The Buyers' Club Keeping Cancer Clinics Independent

A community cancer clinic rarely dies of bad medicine. It dies of bad math. The three-doctor oncology practice on a suburban main street buys the same expensive infusion drugs as a 300-physician hospital system, but without the scale to negotiate the same price. It signs a lease nobody audits. It has no idea whether its overhead is normal, because it can never see anyone else's numbers. Slowly, quietly, the economics tighten - until selling out to the local hospital starts to look less like defeat and more like relief.

Cornerstone Specialty Network, LLC exists to interrupt that story. Founded in 2016 and run out of New Hope, Pennsylvania, Cornerstone is not a hospital, a pharmacy, or a drug company. It is closer to a buyers' club: a network that pools the purchasing power of independent, community-based oncology practices so that a small clinic can negotiate like a large one. The pitch to a cancer doctor is refreshingly unglamorous - better drug rebates, honest benchmarks, and a check on whether you are overpaying for real estate. Do that across hundreds of practices, and you have built what the company describes as the largest independent community-oncology network in the United States.

*Following the April 2024 merger into Provider Network Holdings.

The core ideaSell leverage, not medicine

The mechanism is aggregation. On its own, a small practice takes whatever pricing a base group-purchasing contract offers. Cornerstone stacks value on top of that base. Its Incremental Rebate Program helps members squeeze more out of manufacturer rebates, and its bolt-on drug contracts add rebate and OID agreements that sit on top of a practice's existing deals rather than replacing them. The point is not to rip up what a clinic already has; it is to find the money that a clinic, acting alone, would never have the leverage to reach.

That framing runs through the company's own language. Cornerstone organizes itself around four pillars - Independence, Power, Value, and Support - and they map cleanly onto what it actually sells.

Who it servesThe clinics too small to negotiate

Cornerstone's customers are independent, community-based oncology practices - typically the small to mid-sized clinics that lack the scale, the staff, or the time to negotiate favorable pharmaceutical and operational terms on their own. These are the practices most exposed to consolidation, and the ones with the most to gain from acting collectively. The value proposition is simple arithmetic: a benefit a single practice could never achieve on its own becomes achievable when hundreds of practices move together.

The overlooked line itemYes, they will read your lease

The most telling detail about Cornerstone is not its drug contracts - every oncology GPO has those - but its real estate arm. Through Cornerstone Asset Partners, LLC (CAP), described as the only entity of its kind for community oncology, the network delivers real estate assessments and lease evaluations that flag savings and points of negotiation before a renewal comes due. It goes further into development and alternate-ownership models, including joint-venture structures between hospitals and physician groups.

It is an unsexy service, and that is the point. Rent is one of the quiet places where a clinic bleeds money, and it is exactly the sort of thing a busy oncologist never has time to audit. Bundling it into a membership is a tell about how Cornerstone thinks: the goal is to attack practice economics wherever they leak, not only at the pharmacy counter.

The odd one outWhen a GPO started selling wellness

In 2021, Cornerstone announced wellCORNER, a point-of-care platform that uses tablet and mobile technology to connect cancer patients with science-reviewed natural wellness products - including hemp-derived items such as CBD - delivered to their homes. On its face it reads like a gimmick. In context, it is consistent: if the company's job is to diversify how a clinic earns, then a new, patient-facing revenue line inside the practice fits the thesis rather than contradicting it.

Knowing where you rankBenchmarks for people who can't see each other

Community oncology has a visibility problem: every clinic assumes it is normal because it has nothing to compare against. Cornerstone turns that blind spot into a service. It runs data review meetings - it hosted a community-oncology-focused one in October 2022 - and publishes benchmarking metrics and market data so a practice can move from "I hope we're doing okay" to "here is exactly where we rank." Layer on symposia, webinars, and forums, and the network starts to function as a shared brain for practices that would otherwise operate in isolation.

The 2024 turnFour companies, one network

On April 26, 2024, Cornerstone merged with Altus Biologics, Remedy GPO, and Health Coalition Inc. to form Provider Network Holdings, backed by the private-equity firm Waud Capital Partners. The combined organization supports over 1,500 physicians across 41 states and stretches beyond oncology into neurology, rheumatology, gastroenterology, allergy and immunology, pulmonary, and infectious disease. The pitch broadened accordingly - technology, tools, and services for specialty and biologic drug purchasing, supply-chain management, revenue-cycle management, education, and research.

For a company with roughly two dozen employees, that reach is the whole story. Cornerstone was never built to be large in headcount. It was built to be large in leverage.

The expertiseBuilt by someone who knew the other side

It matters who built this. Founder and CEO Joel Schaedler did not come up through a clinic; he came up through the industry that sells to clinics. Before Cornerstone, he was a vice president at AP Pharma and held roles at P4 Healthcare, with a degree from Kent State University. In other words, he spent years inside the drug economy before building the thing that helps small practices survive it. That background shows in the product mix. Cornerstone reads less like a doctors' cooperative that stumbled into contracting and more like a contracting operation that understands exactly where manufacturer money moves - and how a fragmented buyer loses it.

The leadership bench reflects the same blend. Alongside Schaedler sit a chief commercial officer, a chief financial officer, and a chief medical officer, plus operations and clinical leaders, backed by a Partner Advisory Group of practicing oncologists and practice managers from groups such as Dayton Physicians, Ironwood Cancer Centers, and Astera Cancer Care. It is a deliberate pairing: commercial people who know how to cut deals, and clinical people who keep those deals pointed at patient care rather than away from it.

How the money worksPaid on the volume, not the pitch

The business model is where the strategy becomes legible. Cornerstone is a B2B aggregation network, and it largely earns on the collective volume it assembles rather than on large upfront fees charged to members. Practices plug in and benefit from group-purchasing contracts, incremental rebates, and bolt-on drug agreements; Cornerstone monetizes the scale that those members create together, and layers paid advisory services - benchmarking, real estate, education - on top. That structure is what lets the company say, credibly, that it is on the same side as its members: it does better when its practices buy better, not when they pay more to belong. Alignment like that is rare enough in healthcare that it is worth naming.

The market it sits inA counter-move to consolidation

The backdrop to all of this is a long slide in independent oncology, as hospital systems buy up practices and the economics of running solo get harder every year. Cornerstone's competitors are the other networks and oncology-focused GPOs working the same problem - among them ION Solutions (Cencora), McKesson's US Oncology Network, and OneOncology - along with the hospitals doing the acquiring. What distinguishes Cornerstone's stance is the framing: it treats independence itself as the product, and aggregation as the tool that makes independence pay. The strategy is a kind of consolidation used to resist consolidation.

There is a broader lesson here that has nothing to do with cancer. Any fragmented, high-cost, low-leverage industry has a Cornerstone waiting to be built - a network that lets small operators buy like big ones, see data they could never gather alone, and keep their independence precisely because someone else is doing the negotiating. Cornerstone found that pattern in community oncology, where the stakes happen to be patient care.